• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by T2 Biosystems Inc. (Amendment)

    2/13/24 8:15:02 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care
    Get the next $TTOO alert in real time by email
    SC 13G/A 1 sch13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 1)*
     

     
    T2 Biosystems, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.001 per share
     
     
    (Title of Class of Securities)
     

     
    89853L302
     
     
    (CUSIP Number)
     

     
    December 31, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
    20,370
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    20,370
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    20,370(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.5%
     
    12
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of 20,370 warrants to purchase shares of common stock (the “Warrants”).



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    20,370
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    20,370
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    20,370(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.5%
     
    12
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of 20,370 Warrants.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    20,370
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    20,370
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
    20,370(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.5%
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     
    (1) The reporting person’s ownership consists of 20,370 Warrants.


    Item 1.
    (a)
    Name of Issuer
     
     
    T2 Biosystems, Inc.

    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    101 Hartwell Avenue
    Lexington, Massachusetts 02421

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •   Lind Global Fund II LP, a Delaware limited partnership;
    •   Lind Global Partners II LLC, a Delaware limited liability company; and
    •   Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
     
    Common Stock, $0.001 par value per share
     
    (e)
    CUSIP Number
     
     
    89853L302

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.  Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    Item 6.  Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
    99.1            Joint Filing Agreement by and among the Reporting Persons


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 13, 2024
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton

    Get the next $TTOO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TTOO

    DatePrice TargetRatingAnalyst
    2/18/2022$0.70Neutral → Buy
    Alliance Global Partners
    More analyst ratings

    $TTOO
    SEC Filings

    View All

    Amendment: SEC Form 25-NSE/A filed by T2 Biosystems Inc.

    25-NSE/A - T2 Biosystems, Inc. (0001492674) (Subject)

    7/10/25 4:51:22 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    SEC Form 25-NSE filed by T2 Biosystems Inc.

    25-NSE - T2 Biosystems, Inc. (0001492674) (Subject)

    7/10/25 4:07:38 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by T2 Biosystems Inc.

    8-K - T2 Biosystems, Inc. (0001492674) (Filer)

    4/4/25 5:47:15 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    $TTOO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

    LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.Executed contracts for 27 T2Dx® Instruments in 2024, including

    1/7/25 9:00:00 AM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

    LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel. The target hospitals for the new instruments include: Selling a second T2Dx Instrument to a major reference hospital to expand "same st

    12/18/24 9:00:00 AM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

    LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company's direct-from-whole-blood technology. A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared T2 Biosystems' sepsis tests to blood culture-based diagnostics, and showed that T2 Biosystems' products provided: faster time to detection (e.g., species identification 77 hours faster), faster targeted therapy (

    12/17/24 9:00:00 AM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    $TTOO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Liebman Seymour

    4 - T2 Biosystems, Inc. (0001492674) (Issuer)

    1/2/25 6:58:44 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Commercial Officer Giffin Brett A.

    4 - T2 Biosystems, Inc. (0001492674) (Issuer)

    1/2/25 6:55:13 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Adams Laura Lee

    4 - T2 Biosystems, Inc. (0001492674) (Issuer)

    1/2/25 6:46:12 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    $TTOO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    T2 Biosystems upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded T2 Biosystems from Neutral to Buy and set a new price target of $0.70

    2/18/22 10:16:52 AM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    Alliance Global Partners resumed coverage on T2 Biosystems with a new price target

    Alliance Global Partners resumed coverage of T2 Biosystems with a rating of Neutral and set a new price target of $1.65 from $2.40 previously

    3/5/21 7:31:44 AM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    T2 Biosystems downgraded by Alliance Global Partners with a new price target

    Alliance Global Partners downgraded T2 Biosystems from Buy to Neutral and set a new price target of $2.40 from $2.60 previously

    1/27/21 8:12:03 AM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    $TTOO
    Leadership Updates

    Live Leadership Updates

    View All

    Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

    Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

    7/8/24 8:15:00 AM ET
    $PIRS
    $TTOO
    $FSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer

    LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. As Chief Commercial Officer, Mr. Giffin will join the Company's executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions. Mr. Giffin replaces Anthony Pare, who recently accepted a role as CEO at BioPorto A/S. "We are thrilled to have Brett join T2 Biosystems as Chief Commercial Officer," said John Sperzel, Chairman and CEO at T2

    11/4/21 4:04:00 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    T2 Biosystems Appoints Laura Adams to Its Board of Directors

    LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately. "We are excited to have Laura join the T2 Biosystems Board of Directors," said John Sperzel, Chairman and CEO at T2 Biosystems. "Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory." Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing lead

    10/19/21 4:05:00 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    $TTOO
    Financials

    Live finance-specific insights

    View All

    T2 Biosystems Announces Third Quarter 2024 Financial Results

    LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar

    11/14/24 4:05:00 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

    LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320

    11/5/24 8:00:00 AM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    T2 Biosystems to Host Business Update Call on October 10, 2024

    LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the

    10/8/24 4:05:00 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    $TTOO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by T2 Biosystems Inc.

    SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

    11/14/24 3:38:45 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by T2 Biosystems Inc.

    SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

    11/6/24 9:02:19 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by T2 Biosystems Inc.

    SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

    11/6/24 9:01:48 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care